Discover Compass Pathways' journey in developing COMP360 psilocybin for treatment-resistant depression, tackling regulatory ...

Kamada continues to expect to generate fiscal year 2025 total revenues in the range of $178 million to $182 million, and adjusted EBITDA in the range of $38 million to $42 million, representing a year ...

On both sides of the pond, in both the U.S. and the UK, 2016 was a pivotal year, which has gone on to define the political ...